Ad26 EBOV vaccine

Drug Profile

Ad26 EBOV vaccine

Alternative Names: Ad26 EBOV vaccine - Crucell/NIH; Ad26 EBOV vaccine - NIH/Crucell; Ad26-ZEBOV - Crucell/NIH; Ad26-ZEBOV - NIH/Crucell; Ad26.ZEBOV - Crucell/NIH; Ad26.ZEBOV - NIH/Crucell; Ebola virus vaccine - Crucell/NIH; Ebola virus vaccine - NIH/Crucell

Latest Information Update: 23 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Crucell; National Institutes of Health (USA)
  • Developer Bavarian Nordic; Crucell; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA)
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ebola virus infections

Most Recent Events

  • 08 May 2017 Janssen completes a phase I trial in Ebola virus infections (Prevention) in USA (IM) (NCT02325050)
  • 02 May 2017 The University of Oxford initiates enrolment in the phase I extension PRISM trial for Ebola virus infections (Prevention, Combination therapy) in United Kingdom (NCT03140774)
  • 31 Mar 2017 Phase-II clinical trials in Ebola virus infections (Prevention, In children, In adolescents, In adults, In the elderly) in Guinea and Liberia (IM) (NCT02876328)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top